Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162878 | 1.00 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL1273585 | 1.00 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL66573 | 0.86 | HDAC1 (0.41) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL67491 | 0.86 | HDAC1 (0.41) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL20826464 | 0.86 | HDAC1 (0.41) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL626316 | 0.85 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL13335431 | 0.85 | AAK1 (0.36) | MMP13AAK1HDAC6CTSSCTSK | |
| SCHEMBL7401175 | 0.85 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL626315 | 0.85 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL7401177 | 0.85 | MMP13 (0.39) | MMP13AAK1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508476-B1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA INC (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022139564-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | (주)앰틱스바이오 | 2022-06-30 | — | — | WO | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2020262996-A1 | DERIVATIVE COMPOUND INTRODUCING BIPHENYL GROUP INTO NOVEL AMINOALKANOIC ACID AND ANTIFUNGAL PHARMACEUTICAL COMPOSITION COMPRISING SAME | (주)앰틱스바이오 | 2020-12-30 | — | — | WO | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| EP-1957518-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| CN-101305019-B | New cyclic peptide compounds | ASTELLAS PHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| CN-101305019-A | New cyclic peptide compounds | ASTELLAS PHARMA INC (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1957518-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007049803-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170755-A1 | Cyclic Peptide Compounds | VIP, HAVCR2, EIF2AK2 | MMP13 3159/4885AAK1 2646/4885MEN1 3591/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | MMP13 1359/4885AAK1 2583/4885MEN1 3968/4885 |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, EIF2AK2 | MMP13 3269/4885AAK1 2756/4885MEN1 3864/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | MMP13 2181/4885AAK1 3782/4885MEN1 1814/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | MMP13 2579/4885AAK1 3777/4885MEN1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.